Systematic Financial Management LP Eagle Pharmaceuticals, Inc. Transaction History

Systematic Financial Management LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$37.02 - $51.28 $245,627 - $340,242	-6,635 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$43.24 - $55.02 $142,043 - $180,740	-3,285 Reduced 33.11%	6,635 $318,000
Q1 2020 May 12, 2020	SELL	$34.37 - $60.07 $21,653 - $37,844	-630 Reduced 5.97%	9,920 $456,000
Q4 2019 Feb 14, 2020	BUY	$54.32 - $64.31 $55,678 - $65,917	1,025 Added 10.76%	10,550 $634,000
Q3 2019 Nov 06, 2019	SELL	$53.25 - $59.98 $383,400 - $431,856	-7,200 Reduced 43.05%	9,525 $539,000
Q2 2019 Jul 26, 2019	BUY	$46.61 - $58.45 $779,552 - $977,576	16,725 New	16,725 $931,000
Q3 2018 Nov 06, 2018	SELL	$66.65 - $83.86 $1.27 Million - $1.6 Million	-19,030 Closed	0 $0
Q2 2018 Aug 08, 2018	SELL	$51.25 - $76.62 $252,406 - $377,353	-4,925 Reduced 20.56%	19,030 $1.44 Million
Q1 2018 May 09, 2018	SELL	$52.16 - $66.86 $106,928 - $137,063	-2,050 Reduced 7.88%	23,955 $1.26 Million
Q4 2017 Feb 09, 2018	SELL	$49.6 - $60.87 $8,680 - $10,652	-175 Reduced 0.67%	26,005 $1.39 Million
Q3 2017 Nov 08, 2017	BUY	$46.62 - $60.36 $1.22 Million - $1.58 Million	26,180	26,180 $1.56 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Systematic Financial Management LP, based on Form 13F filings with the SEC.

Stay updated on Systematic Financial Management LP with notifications on news.